Mynvax funding, investors and company details
Mynvax is an emerging Healthcare - Hospitals and Clinic startup from Bengaluru, working in the space of Vaccine Biotechnology / Healthcare Biotechnology. Founded by Gautham Nadig.
- Company: Mynvax Private Limited
- Sector: Healthcare - Hospitals and Clinic
- Location: Bengaluru
- Founders: Gautham Nadig
- Total funding raised: ₹21.63 Cr
Company overview
Mynvax is an Indian clinical-stage vaccine biotechnology company with a clear focus on developing next-generation vaccines for infectious diseases, particularly respiratory viral infections. The company’s core vision is to create novel, improved, and thermostable vaccines that can provide stronger and broader protection while overcoming the limitations of conventional vaccine technologies. The business of Mynvax is centered around the development of recombinant, protein-based vaccines using advanced structure-based protein engineering techniques. By modifying viral proteins such as those found in influenza and COVID-19, the company aims to enhance their stability and ability to trigger a robust immune response. This scientific approach enables the design of vaccines that are not only effective but also safer and more precise in targeting pathogens. A key differentiator for Mynvax is its emphasis on thermostable vaccines, which can remain effective even at higher temperatures. This reduces reliance on cold-chain logistics, making vaccine storage and distribution easier and more cost-effective, especially in developing regions. This innovation positions the company strongly in addressing global healthcare challenges where infrastructure limitations often hinder vaccine accessibility. Mynvax primarily focuses on respiratory diseases such as influenza and COVID-19, with the broader goal of strengthening pandemic preparedness. Its vaccines are designed to offer protection against multiple strains, be rapidly manufacturable at scale, and remain affordable for widespread use. The company follows a research-driven business model, collaborating with academic institutions and industry partners while advancing its vaccine candidates through preclinical and clinical development stages. Overall, Mynvax operates as a deep-tech biotech firm aiming to transform vaccine development by making vaccines more stable, scalable, and accessible, thereby contributing to improved global health outcomes.
Funding rounds
- Latest round (Series A): ₹21.63 Cr. ($ 2.59 Mn), 2024-05-25. Investors: Legacy Assets LLP